ID | 60759 |
フルテキストURL | |
著者 |
Senoo, Satoru
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Miyahara, Nobuaki
Department of Medical Technology, Okayama University Graduate School of Health Sciences
Kaken ID
publons
researchmap
Taniguchi, Akihiko
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
Oda, Naohiro
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Itano, Junko
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Higo, Hisao
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Hara, Naofumi
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Watanabe, Hiromi
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kano, Hirohisa
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Suwaki, Toshimitsu
Department of Respiratory Medicine, Okayama City Hospital
Fuchimoto, Yasuko
Department of Respiratory Medicine, Japan Organization of Occupational Health and Safety Okayama Rosai Hospita
Kajimoto, Kazuhiro
Department of Respiratory Medicine, Japanese Red Cross Kobe Hospita
Ichikawa, Hirohisa
Department of Respiratory Medicine, KKR Takamatsu Hospital
Kudo, Kenichiro
Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center
Shibayama, Takuo
Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center
Tanimoto, Yasushi
Department of Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center
Kaken ID
researchmap
Kuyama, Shoichi
Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center
Kanehiro, Arihiko
Department of Respiratory Medicine, Japan Organization of Occupational Health and Safety Okayama Rosai Hospital
Kaken ID
publons
researchmap
Maeda, Yoshinobu
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
researchmap
Kiura, Katsuyuki
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
Okayama Respiratory Disease Study Group (ORDSG)
|
抄録 | Background
Nintedanib is a multi-kinase inhibitor approved for idiopathic pulmonary fibrosis (IPF); however, its efficacy and safety for patients with IPF and restricted pulmonary function remain unclear. Therefore, the objective of this study was to determine the efficacy and safety of nintedanib for patients with IPF and forced vital capacity (FVC) ≤ 50%.
Methods
This was a multi-center retrospective study performed by the Okayama Respiratory Disease Study Group. Patients were allocated into FVC ≤ 50% and FVC > 50% groups based on their predicted FVC. The primary endpoints were FVC changes from baseline after 6 and 12 months.
Results
45 patients were eligible for the study. 18 patients had FVC ≤ 50%, and 27 patients had FVC > 50%. Overall, 31 and 19 patients underwent pulmonary function tests at 6 and 12 months after initiating nintedanib, respectively. FVC changes from baseline at 6 and 12 months after initiating nintedanib were comparable between the two groups. Adverse events were seen in all patients, and the rates of patients who discontinued nintedanib were also comparable (38.9% vs. 37.0%, p = 1.000). Multiple regression analysis showed that age and forced expiratory volume in 1 second (FEV1)/FVC were negatively correlated with changes in FVC at 6 months after initiating nintedanib.
Conclusions
Our data suggest that nintedanib can be a useful agent for IPF patients, including those with a low FVC, and that age and FEV1/FVC are predictive markers for changes in FVC following nintedanib treatment.
|
発行日 | 2020-08-27
|
出版物タイトル |
PLoS ONE
|
巻 | 15巻
|
号 | 8号
|
出版者 | Public Library of Science
|
開始ページ | e0236935
|
ISSN | 1932-6203
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2020 Senoo et al.
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1371/journal.pone.0236935
|
ライセンス | https://creativecommons.org/licenses/by/4.0/
|